The fifth protease inhibitor, Agenerase (amprenavir)
May 2001
The fifth protease inhibitor, Agenerase (amprenavir), will soon hit the market...from GlaxoSmithKline.
It will be used in combo therapy with other HIV antiretrovirals.
The usual adult dose is 1200 mg (8 capsules) BID.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive